Cold Versus Room Temperature Storage of Platelets for Bleeding in Hematologic Malignancy - a Pilot Trial

Inclusion Criteria: 1. Adult patients (age ≥ 18) admitted to Malignant Hematology ward with hematologic malignancy or marrow aplasia, this may include patients undergoing chemotherapy, immunotherapy, or hematopoietic stem cell transplant or patients admitted for symptom management. 2. Moderate thrombocytopenia, platelet concentration 10-100 x109/L 3. Platelet transfusion ordered to treat bleeding Exclusion Criteria: 1. Severe thrombocytopenia (platelet concentration \<10 x 109/L) 2. Known platelet refractoriness requiring HLA or HPA selected platelet concentrates 3. International normalized ratio (INR) \>2.0 4. Activated partial thromboplastin time (aPTT) \>40 seconds 5. Therapeutic anticoagulation (unfractionated heparin, low molecular weight heparin, warfarin, direct oral anticoagulant) 6. Known congenital bleeding disorder 7. History of unprovoked venous thromboembolic disease 8. Transfusion of platelet concentrate for \>grade 2 bleeding in preceding 24 hours 9. Order for multiple platelet transfusion at once 10. Refusal of blood transfusion 11. Prior participation in CoVeRTS-HM trial 12. Participation in other clinical trials with interventions that may affect CoVeRTS-HM treatment or outcome 13. Unable or unwilling to provide informed consent